Radiodermatitis can be classified as acute or chronic. The acute condition occurs within 90 days of exposure to radiation, whereas the chronic condition may occur from 15 days to 10 years or more after the beginning of radiation therapy. Topical products, oral medications, and dressings are used in the treatment and management of radiodermatitis.
The global radiodermatitis market is estimated to account for US$ 360.5 Mn in terms of value and is expected to reach US$ 472.8 Mn by the end of 2027.
Global Radiodermatitis Market: Drivers
High risk of chronic radiodermatitis after fluoroscopically guided interventions is expected to propel growth of the global radiodermatitis market over the forecast period. For instance, according to the study, ‘Incidence of Chronic Radiodermatitis after Fluoroscopically Guided Interventions: A Retrospective Study’, published in the Journal of Vascular and Interventional Radiology in May 2019, 8.8% of the patients adopting fluoroscopically guided interventions suffered from chronic radiodermatitis.
Global Radiodermatitis Market: Opportunities
Lack of definitive/standard treatment creates ambitious avenue for a breakthrough, thereby offering lucrative growth opportunities for players in the global radiodermatitis market. Radiation dermatitis symptoms are typically managed with a variety of topical agents such as water-based moisturizing creams or lotions, topical steroids, anti-inflammatory emulsions, and wound dressings. However, even with these options, there is no standard treatment currently for the prevention of radiation-induced dermatitis with proven effectiveness. This leads to a tremendous opportunity for the introduction of a breakthrough treatment, which can be considered as standard care and effective in the amelioration of radiation-induced skin damage.
Global Radiodermatitis Market: Restraints
Stringent regulatory scenario is expected to hinder growth of the market. Treatment products for radiation dermatitis are required to undergo clinical trials and approval by regulatory bodies. Conducting trials and filing for approval for novel innovations is a time-consuming process and also requires substantial financial investment. The termination or inefficacy to get a standard treatment through certain studies pertaining to this market could create a deterrent for new players, which could restrain growth of the market.
The global radiodermatitis market was valued at US$ 346.9 Mn in 2019 and is forecast to reach a value of US$ 472.8 Mn by 2027 at a CAGR of 3.9% between 2020 and 2027. Major factor driving the growth of global radiodermatitis market during the forecast period increasing prevalence of cancer, and product launches and approvals for Radiodermatitis treatment.
Topical agents held dominant position in the global radiodermatitis market in 2019, accounting for 70.5% share in terms of value, followed by dressing and oral medication, respectively. Ease of application of topical agents is expected to support growth of the segment.
Retail pharmacies segment held dominant position in the global radiodermatitis market in 2019, accounting for 38.9% share in terms of value.
In New Zealand, Swedish silicon-foam skin dressing, Mepilex Lite (Mölnlycke Health Care, Sweden) is used for the treatment of burns and slow healing wounds. Silver-leaf nylon dressing has proven to have effective antimicrobial activity and enhances healing in burns and skin grafts. Non-adherent dressings such as silicone dressing and no sting barrier film dressings are also recommended for the treatment of radiodermatitis.
E-commerce is a major distribution channel in the market. For instance, 3M offers Cavilon no sting barrier film for online sale on its official website as well as retail websites such as Amazon. RadX, Stratpharma, Molnlycke Health Care, Medline Industries, and Advancis Medical are key players in this market that have their major products available online.
Global Radiodermatitis Market: Competitive Landscape
Major players operating in the global radiodermatitis market include, Acelity, Inc. (3M), BMG Pharma S.r.l., ConvaTec Group PLC, DermaSciences Inc. (Integra LifeSciences Holdings Corporation), Intermed Pharmaceuticals, Molnlycke Health Care, Smith & Nephew Plc, Stratpharma AG, Kannalife, Inc., and Jay Pharma
Global Radiodermatitis Market: Key Developments
September 2019: ConvaTec Group Plc signed an agreement to purchase the assets of Southlake Medical Supplies, Inc., a U.S.-based independent provider of catheter-related supplies
July 2019: Integra LifeSciences Holdings Corporation acquired Arkis Biosciences Inc., a privately-held company that offers a portfolio of neurosurgical devices